Pediatrix Medical Group reported third quarter 2026 net revenue of $501.4 million and adjusted EPS of $0.72, both exceeding analyst expectations. The results were driven by pricing improvements and a favorable shift in payor mix, which helped offset stagnant patient volumes and fading tailwinds from prior-year revenue cycle management collections.

Key Highlights

  • Net revenue grew 1.7% year-over-year to $501.4 million, surpassing the estimated $498.2 million behind acquisition-driven growth.
  • Adjusted EPS of $0.72 beat the $0.65 consensus estimate, supported by a 70 basis point increase in services reimbursed by commercial payors.
  • The company raised its full-year 2026 Adjusted EBITDA guidance floor to $290 million, narrowing the range to $290 million–$300 million.
  • Same-unit patient volume dynamics remained mixed, as a 2.9% increase in office-based services was offset by a 0.1% decline in same-unit NICU days.